

# References

## Chapter 1

- 1 Drews J. Drug discovery: a historical perspective. *Science (New York, NY)*. 2000;**287**(5460):1960–4.
- 2 Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009. National Bureau of Economic Research Working Paper Series. 2012;No. 18235.
- 3 Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. *Pharmacoepidemiology and Drug Safety*. 2011;**20**(6):626–34.
- 4 Gray A. Adverse events and the National Health Service: an economic perspective. University of Oxford; 2003.
- 5 Fu AZ, Jiang JZ, Reeves JH, Fincham JE, Liu GG, Perri M 3rd. Potentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderly. *Medical Care*. 2007;**45**(5):472–6.
- 6 Sellers JA. Medicare drug benefit. *American Journal of Health-System Pharmacy*. 1999;**56**(15):1503.
- 7 Le Grand A, Hogerzeil HV, Haaijer-Ruskamp FM. Intervention research in rational use of drugs: a review. *Health Policy and Planning*. 1999;**14**(2):89–102.
- 8 OECD, Health at a Glance 2011: OECD Indicators. Pharmaceutical expenditure. Available at: <http://www.oecd.org/els/health-systems/49105858.pdf> (last accessed 18 Novembr 2015)
- 9 Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. *New England Journal of Medicine*. 2008;**359**(4):333–5.
- 10 Thorpe KE. The rise in health care spending and what to do about it. *Health Affairs* 2005;**24**(6):1436–45.
- 11 Zuvekas SH, Cohen JW. Prescription drugs and the changing concentration of health care expenditures. *Health Affairs (Project Hope)*. 2007;**26**(1):249–57.
- 12 Malmstrom RE, Godman BB, Diogene E, Baumgartel C, Bennie M, Bishop I, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. *Frontiers in Pharmacology*. 2013;**4**:39.
- 13 Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. *Frontiers in Pharmacology*. 2014;**5**:106.
- 14 Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *Lancet*. 2009;**373**(9659):240–9.
- 15 Gumbs PD, Verschuren WM, Souverein PC, Mantel-Teeuwisse AK, de Wit GA, de Boer A, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. *British Journal of Clinical Pharmacology*. 2007;**64**(5):680–5.
- 16 Lubloy A. Factors affecting the uptake of new medicines: a systematic literature review. *BMC Health Services Research*. 2014;**14**:469.
- 17 Dukes MNG, ed. *Drug Utilization Studies: Methods and Uses*. Copenhagen, WHO Regional Office for Europe, 1993. WHO Regional Publications European Series No. 45.
- 18 Engel A, Siderius P. *The Consumption of Drugs. Report on a Study, 1966–1967*. Copenhagen, WHO Regional Office for Europe, 1968. EURO 3101.
- 19 World Health Organization. *Consumption of Drugs: Report on a Symposium*. Copenhagen, WHO regional Office for Europe, 1970. EURO 3102.

- 20 Bergman U, Elmes P, Halse M, Halvorsen T, Hood H, Lunde PK, et al. The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. *European Journal Of Clinical Pharmacology*. 1975;**8**(2):83–89.
- 21 Bergman U, Grimsson A, Wahba AHW, Westerholm B. *Studies in Drug Utilization. Methods and Applications*. Copenhagen, WHO Regional Publications, 1979. European Series No 8.
- 22 Stolley PD, Lasagna L. Prescribing patterns of physicians. *Journal of Chronic Diseases*. 1969;**22**(6):395–405.
- 23 Hemminki E. Review of literature on the factors affecting drug prescribing. *Social Science & Medicine*. 1975;**9**(2):111–16.
- 24 Mapes R. Aspects of British general practitioners' prescribing. *Medical Care*. 1977;**15**(5):371–81.
- 25 Bergman U. The history of the Drug Utilization Research Group in Europe. *Pharmacoepidemiology and Drug Safety*. 2006;**15**(2):95–8.
- 26 Schubert I. The founding of the EURO-DURG, the European Drug Utilization Research Group. *International Journal of Clinical Pharmacology and Therapeutics*. 1996;**34**(9):410–13.
- 27 1st Meeting of EURO DURG, the European Drug Utilization Research Group. Hungary, 27–30 June 1996. Abstracts. *European Journal of Clinical Pharmacology*. 1997;**52**(3):A19–28.
- 28 Baksaas I, Lunde PKM. National drug policies: the need for drug utilization studies. *Trends in Pharmacological Sciences*. 1986;**7**(4):331–4.
- 29 Crooks J. Methods of audit in drug use. In: Duchene-Marulla ZP, ed. *Advances in Pharmacology and Therapeutics. Proceedings of 7th International Congress of Pharmacology, Paris, 1978*. Oxford, Pergamon Press, 1979: 189–95.
- 30 Sjöqvist F, Agenäs I. Drug utilization studies: implications for medical care. Proceedings from ANIS Symposium, Sånge-Såby, Sweden. *Acta Medica Scandinavica*. 1983;**105**(Suppl. 683).
- 31 Laporte JR, Porta M, Capella D. Drug utilization studies: a tool for determining the effectiveness of drug use. *British Journal of Clinical Pharmacology*. 1983;**16**(3):301–4.
- 32 Lunde PK, Baksaas I. Epidemiology of drug utilization—basic concepts and methodology. *Acta Medica Scandinavica Supplementum*. 1988;**721**:7–11.
- 33 World Health Organization. *How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators*. World Health Organization, 1993. EDM Research Series No. 007.
- 34 McGavock H. *Handbook of Drug Use Research Methodology*. Newcastle upon Tyne, United Kingdom Drug Utilisation Research Group, 2000.
- 35 Lee D, Bergman U. Studies of drug utilization. In: Strom BL, Kimmel SE, Hennessy S, eds. *Pharmacoepidemiology*. Chichester, John Wiley & Sons, 2011.
- 36 World Health Organization. *Introduction to Drug Utilization Research*. Oslo, World Health Organization, 2003.
- 37 Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Ronning M, Vander Stichele RH. Drug utilization research. In: Hartzema AG, Tilson HH, Chan KA, eds. *Pharmacoepidemiology and Therapeutic Risk Management*. Cincinnati, OH, Harvey Whitney Books, 2008.
- 38 Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13–15 May 2004). *European Journal of Clinical Pharmacology*. 2005;**60**(11):831–4.
- 39 Kubacka RT. A primer on drug utilization review. *Journal of the American Pharmaceutical Association*. 1996;**NS36**(4):257–61,279.
- 40 Serradell J, Bjornson DC, Hartzema AG. Drug utilization study methodologies: national and international perspectives. *Drug Intelligence & Clinical Pharmacy*. 1987;**21**(12):994–1001.
- 41 Blackburn JL. Impact of drug usage review on drug utilisation. *Pharmacoeconomics*. 1993;**3**(1):14–21.
- 42 Sigell LT, Nelson DE, Yokel RA, Lorenzi N. Past, present and future of drug information centers as catalysts for the utilization of drug therapy information. *Drug Information Journal*. 1977;**11**(1):11–16.
- 43 Woosley RL. Centers for education and research in therapeutics. *Clinical Pharmacology and Therapeutics*. 1994;**55**(3):249–55.
- 44 Tilson HH, Madre LK, Califf RM. Role of the Centers for Education and Research on Therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics. *Clinical Pharmacology & Therapeutics*. 2007;**82**(2):118–21.
- 45 Buschiazzi H, Vhaves A, Figueras A, Laporte JR. Drug utilization in Latin America – the example of DURG-LA. *WHO Essential Drugs Monitor*. 2003;**032**.
- 46 Hall RC. Drug use in Australia. In: Sjöqvist F, Agenäs I, eds. *Drug utilization studies: implications for medical care. Acta Medica Scandinavica*. 1983;**Suppl. 30**:79–80.

- 
- 47 Hogerzeil HV. Trends in drug utilization research in developing countries. *WHO Drug Information*. 2002;**16**.
- 48 World Health Organization. The selection of essential drugs. Report of a WHO Expert Committee. 1977.
- 49 Strom BL, Kimmel SE, Hennessy S. *Pharmacoepidemiology*. Chichester, John Wiley & Sons, 2011.
- 50 Bergman U. Pharmacoepidemiology – from description to quality assessment: a Swedish perspective. *Norsk epidemiologi*. 2001;**11**(1).
- 51 Gorecka K, Hejdova M, Vander Stichele RH, Linhartova A, Kucera Z, Zemkova M, et al. Abstracts on drug utilization research at seven International Conferences on Pharmacoepidemiology (ICPE): 1996–2002. *Pharmacoepidemiology and Drug Safety*. 2004;**13**(9):621–2.
- 52 Institute of Medicine, Committee on Health Services Research: Training and Work Force Issues. *Health Services Research: Workforce and Educational Issues*. Washington, DC, National Academy Press, 1995.
- 53 Birkett D, Brosen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, et al. Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. *Basic & Clinical Pharmacology & Toxicology*. 2010;**107**(1):531–59.
- 54 American College of Clinical Pharmacy. The definition of clinical pharmacy. *Pharmacotherapy*. 2008;**28**(6):816–17.
- 55 Henshall C, Oortwijn W, Stevens A, Granados A, Banta D. Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting Subgroup of the EUR-ASSESS Project. *International Journal of Technology Assessment in Health Care*. 1997;**13**(2):144–85.
- 56 Clancy CM, Eisenberg JM. Outcomes research: measuring the end results of health care. *Science (New York, NY)*. 1998;**282**(5387):245–6.
- 57 Bootman JL, Townsend RJ, McGhan WF. *Principles of Pharmacoeconomics*. Cincinnati, OH, Harvey Whitney Books Company, 2005.
- 58 World Health Organization. *The Importance of Pharmacovigilance*. World Health Organization, 2002.
- 59 Hirst C, Cook S, Dai W, Perez-Gutthann S, Andrews E. A call for international harmonization in therapeutic risk management. *Pharmacoepidemiology and Drug Safety*. 2006;**15**(12):839–49; disc. 50–1.
- 60 Seiter A. *A Practical Approach to Pharmaceutical Policy*. World Bank Publications, 2010.